We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Renal Cell Carcinoma

Journal Scan / Research · January 04, 2021

Nivolumab + Ipilimumab for First-Line Treatment of Advanced RCC: Extended 4-Year Follow-Up of CheckMate 214

ESMO Open

 

Additional Info

Disclosure statements are available on the authors' profiles:

ESMO Open
Nivolumab Plus Ipilimumab Versus Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma: Extended 4-Year Follow-Up of the Phase III CheckMate 214 Trial
ESMO Open 2020 Nov 01;5(6)e001079, L Albiges, NM Tannir, M Burotto, D McDermott, ER Plimack, P Barthélémy, C Porta, T Powles, F Donskov, S George, CK Kollmannsberger, H Gurney, MO Grimm, Y Tomita, D Castellano, BI Rini, TK Choueiri, SS Saggi, MB McHenry, RJ Motzer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading